NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Price Target & More

$12.27 -0.29 (-2.31 %)
(As of 04/24/2018 01:02 AM ET)
Previous Close$12.27
Today's Range$11.93 - $12.85
52-Week Range$6.30 - $24.38
Volume216,115 shs
Average Volume228,113 shs
Market Capitalization$404.36 million
P/E Ratio-5.76
Dividend YieldN/A
Beta-2.83

About Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals logoSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Receive SYRS News and Ratings via Email

Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SYRS
CUSIPN/A
Phone617-744-1340

Debt

Debt-to-Equity RatioN/A
Current Ratio5.89%
Quick Ratio5.89%

Price-To-Earnings

Trailing P/E Ratio-5.76
Forward P/E Ratio-5.53
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.10 million
Price / Sales359.06
Cash FlowN/A
Price / CashN/A
Book Value$2.40 per share
Price / Book5.11

Profitability

EPS (Most Recent Fiscal Year)($2.13)
Net Income$-54,010,000.00
Net MarginsN/A
Return on Equity-70.81%
Return on Assets-62.77%

Miscellaneous

Employees56
Outstanding Shares32,190,000

How to Become a New Pot Stock Millionaire

Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions

What is Syros Pharmaceuticals' stock symbol?

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

How were Syros Pharmaceuticals' earnings last quarter?

Syros Pharmaceuticals (NASDAQ:SYRS) released its quarterly earnings data on Monday, March, 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.01. View Syros Pharmaceuticals' Earnings History.

When is Syros Pharmaceuticals' next earnings date?

Syros Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Syros Pharmaceuticals.

What price target have analysts set for SYRS?

8 analysts have issued 1-year price objectives for Syros Pharmaceuticals' shares. Their forecasts range from $10.00 to $33.00. On average, they expect Syros Pharmaceuticals' stock price to reach $22.4286 in the next year. View Analyst Ratings for Syros Pharmaceuticals.

What are Wall Street analysts saying about Syros Pharmaceuticals stock?

Here are some recent quotes from research analysts about Syros Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. " (1/20/2018)
  • 2. Cann analysts commented, "Syros announced today that FDA has granted orphan drug designation to SY-1425 for the treatment of acute myeloid leukemia (AML). FDA’s Office of Orphan Drug Products grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States. Orphan drug designation may provide certain benefits, including a seven-year period of market exclusivity if the drug is approved, tax credits for qualified clinical trials and an exemption from FDA application fees." (8/21/2017)

Who are some of Syros Pharmaceuticals' key competitors?

Who are Syros Pharmaceuticals' key executives?

Syros Pharmaceuticals' management team includes the folowing people:
  • Dr. Nancy A. Simonian, Pres, CEO & Director (Age 57)
  • Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 64)
  • Mr. Gerald E. Quirk, Chief Legal & Admin. Officer and Sec. (Age 50)
  • Dr. David A. Roth M.D., Chief Medical Officer (Age 55)
  • Dr. Nathanael S. Gray Ph.D., Scientific Founder and Member of Scientific Advisory Board

When did Syros Pharmaceuticals IPO?

(SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Has Syros Pharmaceuticals been receiving favorable news coverage?

News articles about SYRS stock have been trending somewhat positive on Monday, Accern Sentiment reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a coverage optimism score of 0.22 on Accern's scale. They also gave press coverage about the company an impact score of 45.94 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Syros Pharmaceuticals?

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Syros Pharmaceuticals' stock price today?

One share of SYRS stock can currently be purchased for approximately $12.27.

How big of a company is Syros Pharmaceuticals?

Syros Pharmaceuticals has a market capitalization of $404.36 million and generates $1.10 million in revenue each year. The company earns $-54,010,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Syros Pharmaceuticals employs 56 workers across the globe.

How can I contact Syros Pharmaceuticals?

Syros Pharmaceuticals' mailing address is 620 Memorial Drive Suite300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected]


MarketBeat Community Rating for Syros Pharmaceuticals (SYRS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  300
MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Syros Pharmaceuticals (NASDAQ:SYRS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Syros Pharmaceuticals in the last 12 months. Their average twelve-month price target is $22.4286, suggesting that the stock has a possible upside of 82.79%. The high price target for SYRS is $33.00 and the low price target for SYRS is $10.00. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.752.86
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.4286$22.4286$23.8343$24.4733
Price Target Upside: 82.79% upside79.86% upside139.54% upside48.23% upside

Syros Pharmaceuticals (NASDAQ:SYRS) Consensus Price Target History

Price Target History for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2018HC WainwrightReiterated RatingHold$10.00HighView Rating Details
3/13/2018WedbushReiterated RatingOutperform -> Outperform$11.00 -> $13.00HighView Rating Details
1/8/2018OppenheimerSet Price TargetBuy$28.00HighView Rating Details
12/11/2017CowenReiterated RatingBuyHighView Rating Details
10/31/2017Piper JaffrayReiterated RatingOverweight -> Overweight$30.00N/AView Rating Details
10/23/2017Roth CapitalInitiated CoverageNeutral -> Neutral$15.00N/AView Rating Details
9/28/2017JMP SecuritiesUpgradeMarket Perform -> Outperform$33.00HighView Rating Details
8/21/2017CannReiterated RatingBuy$28.00LowView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Syros Pharmaceuticals (NASDAQ:SYRS) Earnings History and Estimates Chart

Earnings by Quarter for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ:SYRS) Earnings Estimates

2018 EPS Consensus Estimate: ($1.90)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.17)($0.16)($0.17)
Q2 20182($0.55)($0.51)($0.53)
Q3 20182($0.62)($0.53)($0.58)
Q4 20182($0.67)($0.59)($0.63)

Syros Pharmaceuticals (NASDAQ SYRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018N/AView Earnings Details
3/12/2018Q4 2017($0.57)($0.58)ViewN/AView Earnings Details
11/8/2017Q3 2017($0.53)($0.53)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.55)($0.52)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.5920)($0.49)$1.10 millionViewN/AView Earnings Details
3/20/2017Q4 2016($0.6360)($0.47)$0.32 millionViewN/AView Earnings Details
11/14/2016Q316($0.54)($0.65)ViewN/AView Earnings Details
8/15/2016Q2 2016($0.56)($5.42)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Syros Pharmaceuticals (NASDAQ:SYRS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.60%
Institutional Ownership Percentage: 49.33%
Insider Trading History for Syros Pharmaceuticals (NASDAQ:SYRS)
Insider Trading History for Syros Pharmaceuticals (NASDAQ:SYRS)

Syros Pharmaceuticals (NASDAQ SYRS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/31/2018Srinivas AkkarajuDirectorBuy209,424$9.55$1,999,999.20View SEC Filing  
12/15/2017Jeremy P SpringhornInsiderBuy15,000$9.08$136,200.00View SEC Filing  
12/14/2017Srinivas AkkarajuDirectorBuy109,774$9.03$991,259.22View SEC Filing  
10/23/2017Colleen Elizabeth DesimoneInsiderSell550$16.06$8,833.00View SEC Filing  
8/14/2017Richard A YoungDirectorSell3,282$22.00$72,204.00420,101View SEC Filing  
8/7/2017Eric R OlsonInsiderSell2,500$23.59$58,975.002,500View SEC Filing  
7/25/2017Eric R OlsonInsiderSell12,500$21.85$273,125.0012,500View SEC Filing  
7/25/2017Richard A YoungDirectorSell3,282$22.09$72,499.38423,383View SEC Filing  
7/6/2016Redmile Group, LlcMajor ShareholderBuy432,746$12.50$5,409,325.00View SEC Filing  
7/6/2016Robert NelsenDirectorBuy400,000$12.50$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Syros Pharmaceuticals (NASDAQ SYRS) News Headlines

Source:
DateHeadline
Syros Pharmaceuticals (SYRS) Given Average Rating of "Hold" by AnalystsSyros Pharmaceuticals (SYRS) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 18 at 7:24 PM
Syros Pharmaceuticals (SYRS) Upgraded by ValuEngine to "Hold"Syros Pharmaceuticals (SYRS) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 17 at 10:21 PM
Syros Pharmaceuticals (SYRS) Cut to Hold at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:04 AM
Incyte Advances R&D Strategy with Multiple PartnershipsIncyte Advances R&D Strategy with Multiple Partnerships
finance.yahoo.com - April 12 at 11:24 AM
This May Be The Best Time To Look At IncyteThis May Be The Best Time To Look At Incyte
seekingalpha.com - April 11 at 3:45 PM
Syros Pharmaceuticals (SYRS) Downgraded by JMP SecuritiesSyros Pharmaceuticals (SYRS) Downgraded by JMP Securities
www.americanbankingnews.com - April 11 at 12:42 AM
Syros Pharmaceuticals (SYRS) Expected to Announce Quarterly Sales of $5.05 MillionSyros Pharmaceuticals (SYRS) Expected to Announce Quarterly Sales of $5.05 Million
www.americanbankingnews.com - April 9 at 4:27 AM
 Analysts Expect Syros Pharmaceuticals (SYRS) to Post -$0.34 EPS Analysts Expect Syros Pharmaceuticals (SYRS) to Post -$0.34 EPS
www.americanbankingnews.com - April 7 at 3:26 AM
Syros Pharmaceuticals (SYRS) Raised to "Hold" at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 6 at 10:22 PM
Syros Pharmaceuticals (SYRS) Downgraded by BidaskClub to "Hold"Syros Pharmaceuticals (SYRS) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 6 at 10:46 AM
Syros Pharmaceuticals (SYRS) Receives Overweight Rating from Piper JaffraySyros Pharmaceuticals (SYRS) Receives Overweight Rating from Piper Jaffray
www.americanbankingnews.com - April 2 at 8:04 PM
Syros Pharmaceuticals (SYRS) Lowered to Hold at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 7:06 PM
Incyte’s Collaborations and Developments in 2018Incyte’s Collaborations and Developments in 2018
finance.yahoo.com - March 26 at 11:05 AM
Syros Pharmaceuticals (SYRS) Given Consensus Rating of "Buy" by BrokeragesSyros Pharmaceuticals (SYRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 24 at 7:33 PM
BidaskClub Upgrades Syros Pharmaceuticals (SYRS) to "Sell"BidaskClub Upgrades Syros Pharmaceuticals (SYRS) to "Sell"
www.americanbankingnews.com - March 24 at 3:52 PM
Syros Pharmaceuticals (SYRS) Rating Increased to Buy at BidaskClubSyros Pharmaceuticals (SYRS) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 22 at 9:48 AM
 Brokerages Anticipate Syros Pharmaceuticals (SYRS) to Post -$0.34 Earnings Per Share Brokerages Anticipate Syros Pharmaceuticals (SYRS) to Post -$0.34 Earnings Per Share
www.americanbankingnews.com - March 21 at 3:12 AM
Q2 2018 Earnings Forecast for Syros Pharmaceuticals Inc (SYRS) Issued By WedbushQ2 2018 Earnings Forecast for Syros Pharmaceuticals Inc (SYRS) Issued By Wedbush
www.americanbankingnews.com - March 16 at 8:51 AM
Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual MeetingSyros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting
finance.yahoo.com - March 15 at 11:12 AM
Syros Pharmaceuticals Inc (SYRS) to Post Q1 2018 Earnings of ($0.17) Per Share, Oppenheimer ForecastsSyros Pharmaceuticals Inc (SYRS) to Post Q1 2018 Earnings of ($0.17) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - March 15 at 6:26 AM
Syros Pharmaceuticals (SYRS) Earns Hold Rating from HC WainwrightSyros Pharmaceuticals (SYRS) Earns Hold Rating from HC Wainwright
www.americanbankingnews.com - March 14 at 3:14 PM
Wedbush Boosts Syros Pharmaceuticals (SYRS) Price Target to $13.00Wedbush Boosts Syros Pharmaceuticals (SYRS) Price Target to $13.00
www.americanbankingnews.com - March 13 at 3:51 PM
Syros Pharmaceuticals (SYRS) Announces Quarterly  Earnings Results, Misses Estimates By $0.01 EPSSyros Pharmaceuticals (SYRS) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - March 13 at 10:56 AM
BRIEF-Syros Announces Appointment Of Joseph J. Ferra As Chief Financial OfficerBRIEF-Syros Announces Appointment Of Joseph J. Ferra As Chief Financial Officer
www.reuters.com - March 12 at 3:42 PM
Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated MilestonesSyros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
finance.yahoo.com - March 12 at 8:02 AM
Syros Announces Appointment of Joseph J. Ferra as Chief Financial OfficerSyros Announces Appointment of Joseph J. Ferra as Chief Financial Officer
finance.yahoo.com - March 12 at 8:02 AM
Syros Pharmaceuticals (SYRS) Stock Rating Upgraded by BidaskClubSyros Pharmaceuticals (SYRS) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 10 at 11:00 AM
Syros to Present at Upcoming Investor ConferencesSyros to Present at Upcoming Investor Conferences
finance.yahoo.com - March 5 at 11:27 AM
-$0.57 EPS Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter-$0.57 EPS Expected for Syros Pharmaceuticals Inc (SYRS) This Quarter
www.americanbankingnews.com - March 3 at 11:14 PM
Syros Pharmaceuticals Inc (SYRS) Given Consensus Rating of "Buy" by AnalystsSyros Pharmaceuticals Inc (SYRS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 27 at 7:44 PM
Syros Pharmaceuticals Inc (SYRS) Shares Bought by ARK Investment Management LLCSyros Pharmaceuticals Inc (SYRS) Shares Bought by ARK Investment Management LLC
www.americanbankingnews.com - February 27 at 4:24 AM
Syros Pharmaceuticals (SYRS) versus ChemoCentryx (CCXI) Financial ContrastSyros Pharmaceuticals (SYRS) versus ChemoCentryx (CCXI) Financial Contrast
www.americanbankingnews.com - February 25 at 8:30 AM
Syros to Present at Leerink Partners 7th Annual Global Healthcare ConferenceSyros to Present at Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 16 at 9:54 AM
Syros Pharmaceuticals (SYRS) and Myovant Sciences (MYOV) Head to Head ContrastSyros Pharmaceuticals (SYRS) and Myovant Sciences (MYOV) Head to Head Contrast
www.americanbankingnews.com - February 15 at 5:10 PM
Syros Pharmaceuticals Inc (SYRS) Expected to Announce Earnings of -$0.57 Per ShareSyros Pharmaceuticals Inc (SYRS) Expected to Announce Earnings of -$0.57 Per Share
www.americanbankingnews.com - February 15 at 8:58 AM
Syros Announces Pricing of $40 Million Public Offering of Common StockSyros Announces Pricing of $40 Million Public Offering of Common Stock
finance.yahoo.com - February 8 at 5:27 AM
Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional SharesSyros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
finance.yahoo.com - February 8 at 5:27 AM
Syros Pharmaceuticals Inc (SYRS) Given Average Recommendation of "Buy" by AnalystsSyros Pharmaceuticals Inc (SYRS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 2 at 7:42 PM
Syros Pharmaceuticals Inc (SYRS) Director Purchases $1,999,999.20 in StockSyros Pharmaceuticals Inc (SYRS) Director Purchases $1,999,999.20 in Stock
www.americanbankingnews.com - February 2 at 6:16 PM
Syros Pharmaceuticals (SYRS) Prices 4.19M Share Common Offering at $9.55/ShSyros Pharmaceuticals (SYRS) Prices 4.19M Share Common Offering at $9.55/Sh
www.streetinsider.com - February 1 at 5:43 AM
Syros Announces Proposed Offering of Common StockSyros Announces Proposed Offering of Common Stock
finance.yahoo.com - January 31 at 3:17 PM
Syros Pharmaceuticals (SYRS) Announces Proposed $40M Offering of Common StockSyros Pharmaceuticals (SYRS) Announces Proposed $40M Offering of Common Stock
www.streetinsider.com - January 31 at 5:39 AM
FY2020 Earnings Forecast for Syros Pharmaceuticals Inc Issued By Oppenheimer (SYRS)FY2020 Earnings Forecast for Syros Pharmaceuticals Inc Issued By Oppenheimer (SYRS)
www.americanbankingnews.com - January 24 at 8:36 PM
Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα AgonistSyros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα Agonist
finance.yahoo.com - January 22 at 3:21 PM
Syros Pharmaceuticals (SYRS) Downgraded to "Hold" at Zacks Investment ResearchSyros Pharmaceuticals (SYRS) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 20 at 4:08 PM
Zacks: Analysts Anticipate Syros Pharmaceuticals Inc (SYRS) to Post -$0.57 EPSZacks: Analysts Anticipate Syros Pharmaceuticals Inc (SYRS) to Post -$0.57 EPS
www.americanbankingnews.com - January 12 at 9:30 AM
Q1 2018 EPS Estimates for Syros Pharmaceuticals Inc (SYRS) Lifted by OppenheimerQ1 2018 EPS Estimates for Syros Pharmaceuticals Inc (SYRS) Lifted by Oppenheimer
www.americanbankingnews.com - January 11 at 9:36 AM
Q1 2018 Earnings Estimate for Syros Pharmaceuticals Inc Issued By Wedbush (SYRS)Q1 2018 Earnings Estimate for Syros Pharmaceuticals Inc Issued By Wedbush (SYRS)
www.americanbankingnews.com - January 11 at 9:36 AM
Syros Pharmaceuticals Inc (SYRS) Receives Average Recommendation of "Buy" from AnalystsSyros Pharmaceuticals Inc (SYRS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 8 at 5:34 PM
Syros Pharmaceuticals (SYRS) Provides Outline of Strategic Priorities and Expected Milestones for 2018Syros Pharmaceuticals (SYRS) Provides Outline of Strategic Priorities and Expected Milestones for 2018
www.streetinsider.com - January 8 at 4:17 PM

SEC Filings

Syros Pharmaceuticals (NASDAQ:SYRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Syros Pharmaceuticals (NASDAQ SYRS) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.